Sunday 18 October 2026
Export BLSM’s income statement to Excel — free account
BlossomHill Therapeutics, Inc.
BLSM
Insiders bought in the last twelve months.
13.94
1.04
−6.94%
Follow BLSM
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
8.97 | 15.38 |
Net Debt/EBITDA |
2.15 | 2.78 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.77 | 1.02 |
Capex/Depreciation |
(2.42) | (0.26) |
| 59.19% | 0.00% | |
| (44.90%) | 0.00% | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(48.42%) | (31.16%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(19.68) | (13.76) |
Cash per Share |
56.06 | 43.73 |
Shareholders Equity per Share |
51.31 | 43.67 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
51.31 | 43.67 |
Free Cash Flow |
(47.99) | (31.51) |
Working Capital |
123.35 | 97.40 |
Capital Expenditures |
(1.07) | (0.09) |
Net Current Asset Value |
100.95 | 97.40 |
| Other line items | ||
Quick Ratio |
8.83 | 14.79 |
Depreciation/Fixed assets |
0.26 | 0.32 |
Cash ROIC |
(18.33%) | (15.74%) |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(19.25) | (13.72) |
Capex per Share |
(0.44) | (0.04) |
Average Payables |
1.58 | — |
Average Assets |
134.87 | — |
Average Common Equity |
(102.31) | — |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates · fundamentals updated 30 Sep 2026